“Today, Rosatom is conducting pioneering research and development for healthcare purposes, bringing the future closer with each step. Our scientists are truly remarkable as they are both visionaries and dreamers. Their ideas go beyond paper becoming groundbreaking technologies. Their work in additive biotechnology for medical purposes is an example of how scientific thought can become the foundation for technological advancement and benefit humanity,”said Alexey Likhachev.
"Genome editing technologies have already allowed us to 'program' cells, that is to impart necessary properties to them. The scale of this discovery is comparable to that of atomic developments by humanity. In the near future, we will create individual 'parts' for the human body, such as parts of hormone-producing glands or fragments of heart tissue. The technologies that improve quality of life form the basis of a new bioeconomy. We believe that through interdisciplinary synergy, we can establish a solid foundation for the future economy!" - said Vladislav Parfenov, Director of Scientific and Production Center for Medical Devices and Cellular Products (NIITFA JSC).
According to medical studies, cardiovascular disease is the most frequent cause of death worldwide. A particular concern is associated with the frequency of heart valve problems, specifically aortic valve disorders. This condition substantially raises the risk of severe complications and death. The tissue-engineered heart valve is a biomedical cell product that consists of cells, biocompatible materials, and auxiliary substances. This valve is expected to outperform existing mechanical and biological analogues, which have a number of limitations. It will also pave the way for the development of fully functional biological replacements and provide an effective solution for frequently occurring heart valve disorders.
Nuclear energy sources, also known as "nuclear batteries", are miniature radioisotope devices that generate an electrical impulse triggering heart muscle contraction. The nuclear batteries used in pacemakers ensure a virtually unlimited service life for these devices. The solution will help eliminate the need for repeated replacement surgeries, as these devices will be implanted for life.
Rosatom’s Scientific division is dedicated to innovative fundamental and applied research to develop both nuclear and non-nuclear technologies including the closure of the nuclear fuel cycle, thermonuclear fusion, and nuclear medicine. The division also works on science-intensive technologies for both nuclear and other sectors. It consists of 13 research institutes and commercial companies including LUCH Research and Production Association (NII NPO LUCH JSC), State Scientific Research and Design Institute of Rare Metals Industry (Giredmet JSC), V.G. Khlopin Radium Institute, and others. They possess a robust research infrastructure and in-house pilot production facilities, which allow them to implement a scientific idea from basic research to designs and prototypes. The majority of the division’s scientific research and development efforts are taken within the context of the general industrial thematic plan. The scope of the division encompasses testing, developing high-tech medical equipment and innovative construction materials. The division is also running projects aimed at commercializing promising science-intensive technologies.
NIITFA JSC is a specialized institute that conducts research in nuclear physics, nuclear medicine, and other areas of Rosatom’s operations (a company of the Science and Innovations). The Institute was founded in 1960 as the main developer and manufacturer of radiation and medical X-ray equipment. The Institute's developments find their way into the nuclear industry and nuclear power engineering, medicine, oil and gas industry, geology and mining, agriculture, ecology, and other sectors.
The creation of a research molten salt reactor is the next milestone in the progress of technologies for closing the nuclear fuel cycle. Rosatom is running the project in partnership with the Kurchatov National Research Center. The initial phase including the design of the molten salt reactor was completed in 2025.
Molten salt reactors belong to the fourth-generation nuclear energy technology. Their use may reduce the amount and activity of nuclear waste as well as eliminate the need for expensive deep burial sites. Molten salt reactor technology is considered a tool in solving the minor actinides challenge in Russia. It is also part of services provided to international partners interested in reprocessing spent nuclear fuel with minimal release of highly radioactive waste.
Rosatom Ecology Unit plays a crucial role in ensuring the ecological safety in the nuclear industry, the ecological wellbeing of people and sustainable development of the country. Companies within the Unit are dedicated to managing radioactive and hazardous waste (safe storage, reprocessing and disposal), monitoring the environment,remediating contaminated areas (including the removal of radioactive facilities) and rehabilitating the ecosystem. In addition, the Unit develops and implements the closed nuclear fuel cycle technologies, which make it possible to turn nuclear fuel into a renewable resource, as well as to minimize radioactive waste. As part of the "Environmental Wellbeing" national project the Unit is also creating a national system for managing industrial waste of classes I and II. This includes the establishment of processing facilities and the use of digital tools for monitoring waste management.
The Russian "quantum project" involves active work on the development of quantum software: 47 quantum algorithms have been created to solve industrial problems. Rosatom has begun work on pilot applications of quantum computing and launched a large-scale industry program (including over 30 pilot projects focused on optimizing a wide range of production processes, as well as modeling chemical reactions). Among the tasks already solved, there are optimization of production, processing, manufacturing, and supply chains; production scheduling; optimization of NPP construction schedules; and others.
The Future Technologies Forum (FTF) is a platform for discussions about the development of science-intensive technologies in Russia. The Forum was launched in 2023 and has since become a flagship event wh ere leading experts, scientists, business representatives, and government officials gather to discuss the advanced scientific developments and product solutions based on these developments. The Roscongress Foundation is the FTF operator. Rosatom acts as a co-organizer. This year's event has the "Bioeconomics for Humanity" as its main theme.
The field-specific agencies and major Russian companies have a strong focus on improving healthcare services and enhancing access to cutting-edge medicine. Major Russian companies support the comprehensive modernization of the healthcare system and the development of the related infrastructure. Rosatom and its subsidiaries are actively involved in these efforts.